Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 plus exemestane vs placebo plus exemestane in postmenopausal ER+ HER2- advanced breast cancer after NSAI failure (China)
CTR20170589Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in breast cancer, sponsored by Novartis. Started Jun 2017; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20170589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170589.